Contrasting Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Rocket One Inc. Common Stock (NASDAQ:RKTO)

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares Zentalis Pharmaceuticals and Rocket One Inc. Common Stock”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43 million	3.86	-$137.06 million	($1.73)	-2.12
Rocket One Inc. Common Stock	N/A	N/A	-$12.47 million	($0.80)	-1.89

Rocket One Inc. Common Stock has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zentalis Pharmaceuticals and Rocket One Inc. Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Volatility & Risk

Zentalis Pharmaceuticals has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Rocket One Inc. Common Stock has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Insider and Institutional Ownership

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Zentalis Pharmaceuticals and Rocket One Inc. Common Stock, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1	4	2	0	2.14
Rocket One Inc. Common Stock	1	0	1	0	2.00

Zentalis Pharmaceuticals currently has a consensus target price of $5.83, suggesting a potential upside of 59.38%. Rocket One Inc. Common Stock has a consensus target price of $5.00, suggesting a potential upside of 231.13%. Given Rocket One Inc. Common Stock’s higher possible upside, analysts clearly believe Rocket One Inc. Common Stock is more favorable than Zentalis Pharmaceuticals.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.